James S Wilmott

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5626291/publications.pdf

Version: 2024-02-01

145 papers	14,847 citations	44069 48 h-index	20961 115 g-index
151 all docs	151 docs citations	151 times ranked	22587 citing authors

#	Article	IF	Citations
1	Genomic Classification of Cutaneous Melanoma. Cell, 2015, 161, 1681-1696.	28.9	2,562
2	Pan-cancer analysis of whole genomes. Nature, 2020, 578, 82-93.	27.8	1,966
3	Whole-genome landscapes of major melanoma subtypes. Nature, 2017, 545, 175-180.	27.8	1,068
4	Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncology, The, 2018, 19, 672-681.	10.7	732
5	Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma. Clinical Cancer Research, 2012, 18, 1386-1394.	7.0	589
6	Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Cancer Cell, 2019, 35, 238-255.e6.	16.8	547
7	<scp>PD</scp>â€L1 expression in melanoma shows marked heterogeneity within and between patients: implications for antiâ€<scp>PD</scp>â€1/<scp>PD</scp>â€<scp>L</scp>1 clinical trials. Pigment Cell and Melanoma Research, 2015, 28, 245-253.	3.3	356
8	Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. Clinical Cancer Research, 2020, 26, 487-504.	7.0	355
9	CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-NaÃ¯ve Melanoma Patients and Expand Significantly During Antiâ€“PD-1 Treatment. Clinical Cancer Research, 2018, 24, 3036-3045.	7.0	297
10	Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma. American Journal of Surgical Pathology, 2013, 37, 61-65.	3.7	289
11	Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. Clinical Cancer Research, 2018, 24, 1260-1270.	7.0	289
12	UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. Cancer Research, 2015, 75, 5228-5234.	0.9	270
13	Tissue-resident memory CD8+ T cells promote melanomaâ€“immune equilibrium in skin. Nature, 2019, 565, 366-371.	27.8	266
14	Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nature Communications, 2019, 10, 3163.	12.8	205
15	Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. Clinical Cancer Research, 2017, 23, 5024-5033.	7.0	192
16	Programmed death ligand 1 expression in tripleâ€negative breast cancer is associated with tumourâ€infiltrating lymphocytes and improved outcome. Histopathology, 2016, 69, 25-34.	2.9	177
17	MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 15840-15845.	7.1	168
18	Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition. Nature Communications, 2020, 11, 1897.	12.8	165

#	Article	IF	Citations
19	BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma. Journal of Investigative Dermatology, 2013, 133, 509-517.	0.7	156
20	Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. Modern Pathology, 2017, 30, 1666-1676.	5.5	150
21	Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 10995-11000.	7.1	146
22	Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIBâ€“C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. Lancet Oncology, The, 2019, 20, 961-971.	10.7	126
23	PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitorâ€“Treated Melanoma Patients. Clinical Cancer Research, 2015, 21, 3140-3148.	7.0	120
24	Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nature Communications, 2020, 11, 5259.	12.8	102
25	Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma. Nature Cancer, 2021, 2, 693-708.	13.2	102
26	Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Human Molecular Genetics, 2014, 23, 226-238.	2.9	96
27	Atypical Spitzoid Melanocytic Tumors With Positive Sentinel Lymph Nodes in Children and Teenagers, and Comparison With Histologically Unambiguous and Lethal Melanomas. American Journal of Surgical Pathology, 2009, 33, 1386-1395.	3.7	95
28	PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma. Clinical Cancer Research, 2016, 22, 3915-3923.	7.0	91
29	Recurrent inactivating RASA2 mutations in melanoma. Nature Genetics, 2015, 47, 1408-1410.	21.4	90
30	Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours. Nature Communications, 2020, 11, 2408.	12.8	86
31	Epigenetic profiling for the molecular classification of metastatic brain tumors. Nature Communications, 2018, 9, 4627.	12.8	79
32	CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ TÂCells. Immunity, 2020, 53, 805-823.e15.	14.3	79
33	Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine. Molecular Cancer Therapeutics, 2012, 11, 2704-2708.	4.1	78
34	Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Modern Pathology, 2015, 28, 1535-1544.	5.5	76
35	PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors. Clinical Cancer Research, 2017, 23, 6054-6061.	7.0	75
36	RAB27A promotes melanoma cell invasion and metastasis via regulation of proâ€invasive exosomes. International Journal of Cancer, 2019, 144, 3070-3085.	5.1	72

#	Article	IF	Citations
37	Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling. Oncotarget, 2015, 6, 21507-21521.	1.8	72
38	Dynamics of Chemokine, Cytokine, and Growth Factor Serum Levels in BRAF-Mutant Melanoma Patients during BRAF Inhibitor Treatment. Journal of Immunology, 2014, 192, 2505-2513.	0.8	69
39	Sentinel Lymph Node Biopsy in Pediatric and Adolescent Cutaneous Melanoma Patients. Annals of Surgical Oncology, 2010, 17, 138-143.	1.5	68
40	PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. Nature Communications, 2013, 4, 1508.	12.8	67
41	Intrapatient Homogeneity of BRAFV600E Expression in Melanoma. American Journal of Surgical Pathology, 2014, 38, 377-382.	3.7	66
42	DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations. Neuro-Oncology, 2014, 16, 1499-1509.	1.2	65
43	Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell, 2022, 40, 88-102.e7.	16.8	64
44	RIP1 Kinase Is an Oncogenic Driver in Melanoma. Cancer Research, 2015, 75, 1736-1748.	0.9	63
45	Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients. OncoImmunology, 2020, 9, 1659093.	4.6	62
46	Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. OncoImmunology, 2019, 8, e1537581.	4.6	61
47	Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma. Clinical Cancer Research, 2019, 25, 1272-1279.	7.0	57
48	BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma. British Journal of Cancer, 2013, 108, 924-931.	6.4	55
49	Molecular Genomic Profiling of MelanocyticÂNevi. Journal of Investigative Dermatology, 2019, 139, 1762-1768.	0.7	55
50	Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility. International Journal of Cancer, 2019, 144, 1049-1060.	5.1	54
51	Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma. Clinical Cancer Research, 2020, 26, 3671-3681.	7.0	53
52	HDAC inhibitors restore BRAFâ€inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma. International Journal of Cancer, 2018, 142, 1926-1937.	5.1	48
53	Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling. Nature Communications, 2021, 12, 1434.	12.8	46
54	Anatomic position determines oncogenic specificity in melanoma. Nature, 2022, 604, 354-361.	27.8	44

#	Article	IF	Citations
55	Plasma cells in primary melanoma. Prognostic significance and possible role of IgA. Modern Pathology, 2016, 29, 347-358.	5.5	43
56	Skp2-Mediated Stabilization of MTH1 Promotes Survival of Melanoma Cells upon Oxidative Stress. Cancer Research, 2017, 77, 6226-6239.	0.9	43
57	Angiotropism is an independent predictor of microscopic satellites in primary cutaneous melanoma. Histopathology, 2012, 61, 889-898.	2.9	42
58	The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancers. Pathology, 2011, 43, 657-671.	0.6	40
59	Clinicopathologic features associated with efficacy and longâ€term survival in metastatic melanoma patients treated with <scp>BRAF</scp> or combined <scp>BRAF</scp> and MEK inhibitors. Cancer, 2015, 121, 3826-3835.	4.1	40
60	Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas. Laboratory Investigation, 2017, 97, 130-145.	3.7	40
61	Telomere sequence content can be used to determine ALT activity in tumours. Nucleic Acids Research, 2018, 46, 4903-4918.	14.5	40
62	INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas. Oncotarget, 2015, 6, 39891-39907.	1.8	40
63	Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making. Pathology, 2016, 48, 261-266.	0.6	39
64	Effects of <scp>BRAF</scp> inhibitors on human melanoma tissue before treatment, early during treatment, and on progression. Pigment Cell and Melanoma Research, 2013, 26, 499-508.	3.3	37
65	Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. Modern Pathology, 2015, 28, 884-894.	5.5	37
66	The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis in vivo and reduces skin cancer cell migration in vitro. Journal of Pathology, 2012, 226, 451-462.	4.5	36
67	Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value. Journal of Pathology: Clinical Research, 2020, 6, 195-206.	3.0	35
68	Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells. Oncotarget, 2014, 5, 11237-11251.	1.8	34
69	The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene. Science Translational Medicine, 2016, 8, 369ra177.	12.4	33
70	Tumour gene expression signature in primary melanoma predicts long-term outcomes. Nature Communications, 2021, 12, 1137.	12.8	33
71	TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. Oncotarget, 2014, 5, 10127-10139.	1.8	31
72	Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas. Oncotarget, 2019, 10, 930-941.	1.8	31

#	Article	IF	Citations
73	BAP1 expression in cutaneous melanoma: a pilot study. Pathology, 2013, 45, 606-609.	0.6	30
74	Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence. Nature Cancer, 2020, 1, 197-209.	13.2	30
75	Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis. Histopathology, 2012, 61, 702-710.	2.9	29
76	Oncogenic suppression of PHLPP1 in human melanoma. Oncogene, 2014, 33, 4756-4766.	5.9	29
77	BRAF^{V600E} and NRAS^{Q61L/Q61R} mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. Histopathology, 2016, 69, 680-686.	2.9	28
78	Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. OncoImmunology, 2012, 1, 997-999.	4.6	27
79	Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naÃ¯ve Melanoma Patients: Implications for Clinical Trials. Clinical Cancer Research, 2019, 25, 3247-3258.	7.0	27
80	Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases. Pathology, 2019, 51, 39-45.	0.6	25
81	Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis. Genome Medicine, 2021, 13, 81.	8.2	25
82	Targeting NK Cells to Enhance Melanoma Response to Immunotherapies. Cancers, 2021, 13, 1363.	3.7	24
83	The deacylase SIRT5 supports melanoma viability by influencing chromatin dynamics. Journal of Clinical Investigation, 2021, 131, .	8.2	23
84	G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma. Clinical Cancer Research, 2021, 27, 2624-2635.	7.0	22
85	Î³Î´ T Cells in Merkel Cell Carcinomas Have a Proinflammatory Profile Prognostic of Patient Survival. Cancer Immunology Research, 2021, 9, 612-623.	3.4	22
86	LNK suppresses interferon signaling in melanoma. Nature Communications, 2019, 10, 2230.	12.8	21
87	The tumour immune landscape and its implications in cutaneous melanoma. Pigment Cell and Melanoma Research, 2021, 34, 529-549.	3.3	21
88	Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas. Pathology, 2014, 46, 193-198.	0.6	19
89	Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. Pathology, 2016, 48, 194-202.	0.6	19
90	Mutation load in melanoma is affected by <scp>MC</scp>1R genotype. Pigment Cell and Melanoma Research, 2017, 30, 255-258.	3.3	19

#	Article	IF	Citations
91	Brain metastasis DNA methylomes, a novel resource for the identification of biological and clinical features. Scientific Data, 2018, 5, 180245.	5.3	18
92	Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications. Cancer Microenvironment, 2015, 8, 111-118.	3.1	17
93	Interâ€•and intrapatient heterogeneity of indoleamine 2,3â€dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment. Histopathology, 2019, 74, 817-828.	2.9	16
94	Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model. PLoS ONE, 2020, 15, e0226444.	2.5	16
95	Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy. , 2022, 10, e004771.		16
96	Melanoma protective antitumor immunity activated by catalytic DNA. Oncogene, 2018, 37, 5115-5126.	5.9	15
97	Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma. Journal of Clinical Investigation, 2021, 131, .	8.2	15
98	The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma. Frontiers in Oncology, 2018, 8, 584.	2.8	14
99	Genetic drivers of nonâ€cutaneous melanomas: Challenges and opportunities in a heterogeneous landscape. Experimental Dermatology, 2022, 31, 13-30.	2.9	14
100	Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (<0.1Âmm) Sentinel Lymph Node Metastases. Annals of Surgical Oncology, 2015, 22, 2972-2977.	1.5	13
101	Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas. Cancer Immunology Research, 2020, 8, 1346-1353.	3.4	13
102	Differences in LC3B expression and prognostic implications in oropharyngeal and oral cavity squamous cell carcinoma patients. BMC Cancer, 2018, 18, 624.	2.6	12
103	Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors. Frontiers in Oncology, 2020, 10, 757.	2.8	11
104	Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/â^' Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets. Cancers, 2021, 13, 3186.	3.7	11
105	The prognostic value of tumor mitotic rate in children and adolescents with cutaneous melanoma: A retrospective cohort study. Journal of the American Academy of Dermatology, 2020, 82, 910-919.	1.2	10
106	Molecular Profiling of Noncoding Mutations Distinguishes Nevoid Melanomas From Mitotically Active Nevi in Pregnancy. American Journal of Surgical Pathology, 2020, 44, 357-367.	3.7	10
107	Intra-patient heterogeneity of BRAF mutation status: fact or fiction?. British Journal of Cancer, 2014, 111, 1678-1679.	6.4	9
108	Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes. Pathology, 2015, 47, 683-693.	0.6	9

#	Article	IF	Citations
109	Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis. British Journal of Cancer, 2018, 119, 713-723.	6.4	9
110	Evaluation of Crizotinib Treatment in a Patient With Unresectable GOPC-ROS1 Fusion Agminated Spitz Nevi. JAMA Dermatology, 2021, 157, 836-841.	4.1	9
111	Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling Melanoma. Frontiers in Molecular Biosciences, 2022, 9, .	3.5	9
112	High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy. Genes, 2021, 12, 1629.	2.4	8
113	Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis. Pathology, 2021, 53, 830-835.	0.6	7
114	Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation. , 2022, 10, e004095.		7
115	Abstract 5734: Gut microbiota predicts response and toxicity with neoadjuvant immunotherapy. , 2020, , .		6
116	How anti-PD1 treatments are changing the management of melanoma. Melanoma Management, 2014, 1, 165-172.	0.5	5
117	The â€œTricky Businessâ€•of Identifying Mechanisms of Resistance to Antiâ€“PD-1. Clinical Cancer Research, 2017, 23, 2921-2923.	7.0	5
118	Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy?. Melanoma Management, 2015, 2, 15-19.	0.5	4
119	Multiparameter analysis of naevi and primary melanomas identifies a subset of naevi with elevated markers of transformation. Pigment Cell and Melanoma Research, 2016, 29, 444-452.	3.3	3
120	Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma. Pathology, 2022, 54, 533-540.	0.6	3
121	Comprehensive Clinical, Histopathologic, and Molecular Analysis and Long-term Follow-up of Patients With Nodal Blue Nevi. American Journal of Surgical Pathology, 2022, 46, 1048-1059.	3.7	3
122	Abstract 975: Liver metastases (mets) induce systemic immunosuppression and immunotherapy resistance in metastatic melanoma. , 2019, , .		2
123	Distinct gene expression, mutational profile and clinical outcomes of V600E and V600K/R BRAF-mutant metastatic melanoma (MM).. Journal of Clinical Oncology, 2017, 35, 9541-9541.	1.6	2
124	Abstract 2822: Low intestinal microbial diversity is associated with severe immune-related adverse events and lack of response to neoadjuvant combination antiPD1, anti-CTLA4 immunotherapy. , 2019, , .		2
125	Reply to comment on: Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (<Â0.1Âmm) Sentinel Lymph Node Metastases. Annals of Surgical Oncology, 2017, 24, 660-660.	1.5	1
126	Advantages of whole-genome sequencing for identification of tumor etiology and clinically actionable genomic aberrations: lessons from the Australian Melanoma Genome Project. Melanoma Management, 2017, 4, 147-149.	0.5	1

#	Article	IF	Citations
127	Novel Immune Targets in Melanomaâ€"Response. Clinical Cancer Research, 2019, 25, 5424-5425.	7.0	1
128	bcGSTâ€"an interactive bias-correction method to identify over-represented gene-sets in boutique arrays. Bioinformatics, 2019, 35, 1350-1357.	4.1	1
129	Mucosal Melanoma. Surgical Pathology Clinics, 2021, 14, 293-307.	1.7	1
130	Abstract 913: Defining melanoma patients unresponsive to single agent anti-PD-1 therapy but responsive to combination anti-PD-1 + anti-CTLA-4 therapy. Cancer Research, 2020, 80, 913-913.	0.9	1
131	Multiple eruptive squamoproliferative lesions during antiâ€PD1 immunotherapy for metastatic melanoma: Pathogenesis, immunohistochemical analysis and treatment. Dermatologic Therapy, 2022, , e15472.	1.7	1
132	Association of baseline corticosteroid treatment with outcomes for patients (pts) with BRAF-mutant melanoma brain metastases (MBMs) in COMBI-MB treated with dabrafenib and trametinib (DT).. Journal of Clinical Oncology, 2022, 40, e21546-e21546.	1.6	1
133	A light shines on melanoma metastagenesis. Pigment Cell and Melanoma Research, 2014, 27, 696-697.	3.3	0
134	Abstract B67: Galectin-1 expression related to hypoxia in primary human melanoma as a driver for metastatic progression. A target to promote anticancer immunotherapy.. , 2013, , .		0
135	Abstract B8: Galectin-1 expressed in human melanoma is bound to cancer stem cells: A driver for metastatic progression and target for antimetastatic cancer therapy. , 2013, , .		0
136	PD-L1 expression, immune cell correlates, and PD-1+ lymphocytes in sentinel lymph node positive melanoma patients: Implications for adjuvant PD-1 clinical trials.. Journal of Clinical Oncology, 2015, 33, e20011-e20011.	1.6	0
137	Abstract 56: Receptor-Interacting protein kinase 1 functions as an oncogenic regulator in human melanoma. , 2015, , .		0
138	Abstract 5025: Immune expression profiling of MAPK inhibitor resistant tumors based upon mechanisms of resistance. , 2015, , .		0
139	Abstract 4718: Inositol polyphosphate 4-phosphatase II activates PI3K/SGK3 signaling to promote proliferation of human melanoma cells. , 2015, , .		0
140	Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy.. Journal of Clinical Oncology, 2017, 35, 51-51.	1.6	0
141	Abstract 2206: Proteome phenotype of stage III metastatic melanoma and response to MEK inhibition. , 2017, , .		0
142	Abstract LB-146: T cell receptor immunosequencing improves prediction of melanoma recurrence. , 2018, , .		0
143	Abstract 2420: Skp2-mediated stabilization of MTH1 promotes survival of melanoma cells upon oxidative stress. , 2018, , .		0
144	Abstract 3246: Dynamics of T-cell checkpoint receptor profiles during melanoma progression. , 2019, , .		0

#	Article	IF	Citations
145	A biomarker-guided Bayesian response-adaptive phase II trial for metastatic melanoma: The Personalized Immunotherapy Platform (PIP) trial design.. Journal of Clinical Oncology, 2022, 40, TPS9599-TPS9599.	1.6	0